Pacific EdgeASX:PEB -3.85%42 FCF Margin % is -233.46% as of Mar. 2026. GuruFocus rates ASX:PEB with a GF Score™ of 42/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Pacific Edge ranks worse than 87.25% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pacific Edge's Free Cash Flow for the
six
months ended in Mar. 2026 was A$-10.82 Mil. Pacific Edge's Revenue for the
six
months ended in Mar. 2026 was A$4.63 Mil. Therefore, Pacific Edge's FCF Margin % for the quarter that ended in Mar. 2026 was -233.46%.
The historical rank and industry rank for Pacific Edge's FCF Margin % or its related term are showing as below:
ASX:PEB'
s FCF Margin % Range Over the Past 10 Years
Min: -542.21 Med: -204.16 Max: -113.45
Current: -280.4
During the past 13 years, the highest FCF Margin % of Pacific Edge was -113.45%. The lowest was -542.21%. And the median was -204.16%.
ASX:PEB's FCF Margin % is ranked worse than 87.25% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs ASX:PEB: -280.40
Pacific Edge FCF Margin % Related Terms
Pacific Edge FCF Margin % Historical Data
* Premium members only.
The historical data trend for Pacific Edge's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PEB vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Pacific Edge's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Edge FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Pacific Edge's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Edge (ASX:PEB) has a FCF Margin % of -233.46% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pacific Edge and its competitors. According to the industry distribution chart, Pacific Edge ranks #178 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 87.3%.
Is Pacific Edge's FCF Margin % too high?
Pacific Edge's current FCF Margin % is -233.46%. Based on the distribution chart, Pacific Edge ranks #178 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #178 out of 204 companies for FCF Margin %. This places Pacific Edge in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pacific Edge and its competitors. Pacific Edge's current FCF Margin % is -233.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.25 — trading 400% above its estimated fair value. The current FCF Margin % is -233.46%. Pacific Edge's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current FCF Margin % is -233.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Edge (ASX:PEB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued.
The current stock price of A$0.25 is trading 400% above its estimated GF Value™ of A$0.05.
GuruFocus considers Pacific Edge to be Significantly Overvalued.
Key valuation signals for ASX:PEB:
FCF Margin %: -233.46%
GF Value™: A$0.05 vs. price of A$0.25 (400% above fair value)
No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score
Get the complete analysis for ASX:PEB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PEB has been successfully added to your 
